Marie O Pohl, Laura Martin-Sancho, Ranjala Ratnayake, Kris M White, Laura Riva, Qi-Yin Chen, Gauthier Lieber, Idoia Busnadiego, Xin Yin, Samuel Lin, Yuan Pu, Lars Pache, Romel Rosales, Marion Déjosez, Yiren Qin, Paul D De Jesus, Anne Beall, Sunnie Yoh, Benjamin G Hale, Thomas P Zwaka, Naoko Matsunaga, Adolfo García-Sastre, Silke Stertz, Sumit K Chanda, Hendrik Luesch
There is a pressing need for host-directed therapeutics that elicit broad-spectrum antiviral activities to potentially address current and future viral pandemics. Apratoxin S4 (Apra S4) is a potent Sec61 inhibitor that prevents cotranslational translocation of secretory proteins into the endoplasmic reticulum (ER), leading to anticancer and antiangiogenic activity both in vitro and in vivo. Since Sec61 has been shown to be an essential host factor for viral proteostasis, we tested Apra S4 in cellular models of viral infection, including SARS-CoV-2, influenza A virus, and flaviviruses (Zika, West Nile, and Dengue virus)...
July 8, 2022: ACS Infectious Diseases